Carfilzomib BOS 30 mg Powder for solution for injection/infusion Vial

Product Overview

Experience targeted therapy with Carfilzomib BOS 30 mg Powder for Solution for Injection/Infusion, a potent medication designed for the treatment of multiple myeloma.

For comprehensive information on specialized pharmaceuticals, you can refer to leading platforms such as Nahdi Online, , and , where similar high-quality medications are detailed.

This product delivers a precise dosage of Carfilzomib, a selective proteasome inhibitor. It works by disrupting cellular processes crucial for cancer cell survival and proliferation, thereby helping to manage disease progression.

This sterile powder, packaged in a single vial, is reconstituted and administered intravenously by healthcare professionals, ensuring accurate and controlled delivery for optimal patient outcomes.

Benefits of Use

• Effectively targets and inhibits proteasomes in multiple myeloma cells, leading to apoptosis (programmed cell death) of cancer cells.
• Contributes to improved progression-free survival in patients with relapsed or refractory multiple myeloma.
• Often used as part of a combination therapy regimen to enhance treatment efficacy.
• A critical component in managing a complex hematological malignancy.

How to Use

1. Carfilzomib BOS 30 mg must be administered by a qualified healthcare professional experienced in oncology treatment.
2. The powder should be reconstituted using sterile water for injection according to the specific instructions provided in the product's prescribing information.
3. It is administered as an intravenous (IV) infusion, typically over a duration of 10 or 30 minutes, depending on the treatment protocol.
4. Dosage is determined based on the patient's body surface area (BSA) and specific treatment cycles (e.g., 21-day cycles).
5. Patients may require pre-medication (e.g., with dexamethasone) to minimize the risk of infusion-related reactions.
6. Close monitoring of the patient's condition, including blood counts and organ function, is essential throughout the treatment course.

Caution & Warnings

• Cardiac Events: Carfilzomib can cause or worsen cardiac conditions, including heart failure, myocardial ischemia, and arrhythmia. Patients with a history of cardiac disease should be closely monitored.
• Pulmonary Hypertension: Cases of pulmonary hypertension, sometimes severe, have been reported. Monitor for signs and symptoms such as dyspnea or edema.
• Acute Renal Failure: Acute renal failure can occur. Ensure adequate hydration and monitor renal function.
• Hepatic Toxicity: Severe and fatal cases of hepatic veno-occlusive disease have been observed. Monitor liver function tests regularly.
• Infusion Reactions: Infusion-related reactions, including fever, chills, dyspnea, and chest pain, can occur. Pre-medication may help mitigate these.
• Thrombotic Microangiopathy (TMA): Cases of TMA, including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), have been reported.
• Posterior Reversible Encephalopathy Syndrome (PRES): PRES has been reported in patients receiving Carfilzomib.
• Embryo-Fetal Toxicity: Carfilzomib can cause fetal harm. Avoid use in pregnant women and advise reproductive potential patients to use effective contraception.
• Tumor Lysis Syndrome: Patients with a high tumor burden are at risk of Tumor Lysis Syndrome.
• Venous Thrombosis: Increased risk of venous thromboembolism.

Ingredients

• Active Ingredient: Carfilzomib 30 mg
• Excipients: Typically includes sulfobutylether beta-cyclodextrin sodium, mannitol, anhydrous citric acid, and sodium hydroxide.

Product Details

• Strength: 30 mg
• Dosage Form: Powder for solution for injection/infusion
• Package Type: Vial
• Storage Conditions: Store in a refrigerator (2°C - 8°C). Protect from light.